Is BioNTech Stock a Buy?
_0.png?locale=de){kind=logo}
Of the 52 vaccines being tested on humans in clinical trials, there are three primary types. Some use a dead or weakened virus to bring coronavirus genes into the cells and create an immune response. Others contain fragments or even whole proteins from the coronavirus, but no genetic material to invoke the immune system. Finally, genetic vaccines use genetic material to cause the body to create a protein from the virus, and then the immune system recognizes the virus and attacks it.
BioNTech (NASDAQ: BNTX) and partner Pfizer (NYSE: PFE) are creating a genetic vaccine candidate that just gave all of humanity a jolt of optimism with the announcement of interim results from its phase 3 clinical trial. But while the vaccine, called BNT162b2, would obviously be a huge driver of the company's revenue in the near term, there is more to BioNTech's long-term outlook than just this one drug. The company's successful development of messenger ribonucleic acid (mRNA) as a method of triggering the immune system could provide a platform for the treatment of many other diseases. Given the run up in the stock after the positive news, investors have to ask: Is BioNTech stock a buy?
Image source: Getty Images.
Source Fool.com
